BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cofiell R, Kukreja A, Bedard K, Yan Y, Mickle AP, Ogawa M, Bedrosian CL, Faas SJ. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood 2015;125:3253-62. [PMID: 25833956 DOI: 10.1182/blood-2014-09-600411] [Cited by in Crossref: 109] [Cited by in F6Publishing: 96] [Article Influence: 15.6] [Reference Citation Analysis]
Number Citing Articles
1 Gediz F, Payzin BK, Ecemis S, Güler N, Yilmaz AF, Topcugil F, Berdeli A. Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey. Transfusion and Apheresis Science 2016;55:357-62. [DOI: 10.1016/j.transci.2016.09.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
2 Puri P, Hanxhiu A, O'Hara DV, Hsu D, Vucak-Dzumhur M. A life-threatening case of pregnancy-related atypical Haemolytic uremic syndrome and successful treatment with Eculizumab. BMC Nephrol 2020;21:488. [PMID: 33203373 DOI: 10.1186/s12882-020-02100-4] [Reference Citation Analysis]
3 Remick DG, Ayala A, Chaudry IH, Coopersmith CM, Deutschman C, Hellman J, Moldawer L, Osuchowski MF. Premise for Standardized Sepsis Models. Shock 2019;51:4-9. [PMID: 29877959 DOI: 10.1097/SHK.0000000000001164] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 10.5] [Reference Citation Analysis]
4 Thurman JM. Complement Biomarkers of Hemolytic Uremic Syndrome-If Not One Thing, Maybe Another. Mayo Clin Proc 2018;93:1337-9. [PMID: 30286826 DOI: 10.1016/j.mayocp.2018.08.024] [Reference Citation Analysis]
5 Raina R, Sethi SK, Dragon-Durey MA, Khooblall A, Sharma D, Khandelwal P, Shapiro R, Boyer O, Yap HK, Bagga A, Licht C. Systematic review of atypical hemolytic uremic syndrome biomarkers. Pediatr Nephrol 2022. [PMID: 35118546 DOI: 10.1007/s00467-022-05451-2] [Reference Citation Analysis]
6 Brusov OS, Senko OV, Kodryan MS, Kuznetsova AV, Matveev IA, Oleichik IV, Karpova NS, Faktor MI, Aleshenko AV, Sizov SV. [Application of machine learning for predicting the outcome of treatment of patients with schizophrenia according to the indicators of «Thrombodynamics» test]. Zh Nevrol Psikhiatr Im S S Korsakova 2021;121:45-53. [PMID: 34481435 DOI: 10.17116/jnevro202112108145] [Reference Citation Analysis]
7 Sakurai S, Kato H, Yoshida Y, Sugawara Y, Fujisawa M, Yasumoto A, Matsumoto M, Fujimura Y, Yatomi Y, Nangaku M. Profiles of Coagulation and Fibrinolysis Activation-Associated Molecular Markers of Atypical Hemolytic Uremic Syndrome in the Acute Phase. J Atheroscler Thromb 2020;27:353-62. [PMID: 31484852 DOI: 10.5551/jat.49494] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
8 Carr JM, Cabezas-Falcon S, Dubowsky JG, Hulme-Jones J, Gordon DL. Dengue virus and the complement alternative pathway. FEBS Lett 2020;594:2543-55. [PMID: 31943152 DOI: 10.1002/1873-3468.13730] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
9 Roe K. Potential New Treatments for Kawasaki Disease, Its Variations, and Multisystem Inflammatory Syndrome. SN Compr Clin Med 2021;:1-5. [PMID: 33786417 DOI: 10.1007/s42399-021-00872-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Rodriguez E, Barrios C, Soler MJ. Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome? Clin Kidney J 2017;10:320-2. [PMID: 28616209 DOI: 10.1093/ckj/sfx024] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
11 Tavener SK, Jewell DE, Panickar KS. The Increase in Circulating Levels of Pro-Inflammatory Chemokines, Cytokines, and Complement C5 in Canines with Impaired Kidney Function. CIMB 2022;44:1664-76. [DOI: 10.3390/cimb44040114] [Reference Citation Analysis]
12 Oncul S, Afshar-Kharghan V. The interaction between the complement system and hemostatic factors. Curr Opin Hematol 2020;27:341-52. [PMID: 32701617 DOI: 10.1097/MOH.0000000000000605] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
13 Moriarty RD, Cox A, McCall M, Smith SG, Cox D. Escherichia coli induces platelet aggregation in an FcγRIIa-dependent manner. J Thromb Haemost 2016;14:797-806. [PMID: 26669970 DOI: 10.1111/jth.13226] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
14 Winkler MS, Skirecki T, Brunkhorst FM, Cajander S, Cavaillon JM, Ferrer R, Flohé SB, García-Salido A, Giamarellos-Bourboulis EJ, Girardis M, Kox M, Lachmann G, Martin-Loeches I, Netea MG, Spinetti T, Schefold JC, Torres A, Uhle F, Venet F, Weis S, Scherag A, Rubio I, Osuchowski MF. Bridging animal and clinical research during SARS-CoV-2 pandemic: A new-old challenge. EBioMedicine 2021;66:103291. [PMID: 33813139 DOI: 10.1016/j.ebiom.2021.103291] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Harris CL, Pouw RB, Kavanagh D, Sun R, Ricklin D. Developments in anti-complement therapy; from disease to clinical trial. Mol Immunol 2018;102:89-119. [PMID: 30121124 DOI: 10.1016/j.molimm.2018.06.008] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 10.3] [Reference Citation Analysis]
16 Xu P, Wang X, Qian J, Li Z, Yao J, Xu A. The prognostic evaluation of CA19-9, D-dimer and TNFAIP3/A20 in patients with pancreatic ductal adenocarcinoma. Medicine (Baltimore) 2021;100:e24651. [PMID: 33578593 DOI: 10.1097/MD.0000000000024651] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Shanmugalingam R, Hsu D, Makris A. Pregnancy-induced atypical haemolytic uremic syndrome: A new era with eculizumab. Obstet Med 2018;11:28-31. [PMID: 29636811 DOI: 10.1177/1753495X17704563] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
18 Macia M, de Alvaro Moreno F, Dutt T, Fehrman I, Hadaya K, Gasteyger C, Heyne N. Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome. Clin Kidney J. 2017;10:310-319. [PMID: 28621343 DOI: 10.1093/ckj/sfw115] [Cited by in Crossref: 8] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
19 Chonat S, Arthur CM, Zerra PE, Maier CL, Jajosky RP, Yee MEM, Miller MJ, Josephson CD, Roback JD, Fasano R, Stowell SR. Challenges in preventing and treating hemolytic complications associated with red blood cell transfusion. Transfus Clin Biol 2019;26:130-4. [PMID: 30979566 DOI: 10.1016/j.tracli.2019.03.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
20 Kim SH, Kim HY, Kim SY. Atypical hemolytic uremic syndrome and eculizumab therapy in children. Korean J Pediatr 2018;61:37-42. [PMID: 29563942 DOI: 10.3345/kjp.2018.61.2.37] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
21 Krishnappa V, Gupta M, Elrifai M, Moftakhar B, Ensley MJ, Vachharajani TJ, Sethi SK, Raina R. Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens: Meta-Analysis of Atypical HUS Case Reports. Therapeutic Apheresis and Dialysis 2018;22:178-88. [DOI: 10.1111/1744-9987.12641] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
22 Ekdahl KN, Teramura Y, Hamad OA, Asif S, Duehrkop C, Fromell K, Gustafson E, Hong J, Kozarcanin H, Magnusson PU, Huber-Lang M, Garred P, Nilsson B. Dangerous liaisons: complement, coagulation, and kallikrein/kinin cross-talk act as a linchpin in the events leading to thromboinflammation. Immunol Rev 2016;274:245-69. [PMID: 27782319 DOI: 10.1111/imr.12471] [Cited by in Crossref: 71] [Cited by in F6Publishing: 71] [Article Influence: 14.2] [Reference Citation Analysis]
23 Berger BE. Atypical hemolytic uremic syndrome: a syndrome in need of clarity. Clin Kidney J 2019;12:338-47. [PMID: 31198222 DOI: 10.1093/ckj/sfy066] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
24 Chauhan AJ, Wiffen LJ, Brown TP. COVID-19: A collision of complement, coagulation and inflammatory pathways. J Thromb Haemost 2020;18:2110-7. [PMID: 32608159 DOI: 10.1111/jth.14981] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 22.0] [Reference Citation Analysis]
25 Emirova K, Volokhina E, Tolstova E, van den Heuvel B. Recovery of renal function after long-term dialysis and resolution of cardiomyopathy in a patient with aHUS receiving eculizumab. BMJ Case Rep 2016;2016:bcr2015213928. [PMID: 26880823 DOI: 10.1136/bcr-2015-213928] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
26 Le Quintrec M, Lapeyraque AL, Lionet A, Sellier-Leclerc AL, Delmas Y, Baudouin V, Daugas E, Decramer S, Tricot L, Cailliez M, Dubot P, Servais A, Mourey-Epron C, Pourcine F, Loirat C, Frémeaux-Bacchi V, Fakhouri F. Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy. Am J Kidney Dis 2018;72:84-92. [PMID: 29429752 DOI: 10.1053/j.ajkd.2017.11.019] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 12.0] [Reference Citation Analysis]
27 Pugh D, O'Sullivan ED, Duthie FA, Masson P, Kavanagh D. Interventions for atypical haemolytic uraemic syndrome. Cochrane Database Syst Rev 2021;3:CD012862. [PMID: 33783815 DOI: 10.1002/14651858.CD012862.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Mulay SR, Kumar SV, Lech M, Desai J, Anders HJ. How Kidney Cell Death Induces Renal Necroinflammation. Semin Nephrol 2016;36:162-73. [PMID: 27339382 DOI: 10.1016/j.semnephrol.2016.03.004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
29 Mulay SR, Linkermann A, Anders HJ. Necroinflammation in Kidney Disease. J Am Soc Nephrol 2016;27:27-39. [PMID: 26334031 DOI: 10.1681/ASN.2015040405] [Cited by in Crossref: 115] [Cited by in F6Publishing: 59] [Article Influence: 16.4] [Reference Citation Analysis]
30 Dixon BP, Gruppo RA. Atypical Hemolytic Uremic Syndrome. Pediatric Clinics of North America 2018;65:509-25. [DOI: 10.1016/j.pcl.2018.02.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
31 Huang J, Cui Z, Gu QH, Zhang YM, Qu Z, Wang X, Wang F, Cheng XY, Meng LQ, Liu G, Zhao MH. Complement activation profile of patients with primary focal segmental glomerulosclerosis. PLoS One 2020;15:e0234934. [PMID: 32569286 DOI: 10.1371/journal.pone.0234934] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
32 Leatherdale A, Stukas S, Lei V, West HE, Campbell CJ, Hoiland RL, Cooper J, Wellington CL, Sekhon MS, Pryzdial ELG, Conway EM. Persistently elevated complement alternative pathway biomarkers in COVID-19 correlate with hypoxemia and predict in-hospital mortality. Med Microbiol Immunol 2022. [PMID: 35034207 DOI: 10.1007/s00430-021-00725-2] [Reference Citation Analysis]
33 Song D, Liu X, Chen Z, Xiao H, Ding J, Sun S, Liu H, Guo W, Wang S, Yu F, Zhao M; On Behalf of the Chinese Renal–TMA Network Institutes. The clinical and laboratory features of Chinese Han anti-factor H autoantibody-associated hemolytic uremic syndrome. Pediatr Nephrol 2017;32:811-22. [DOI: 10.1007/s00467-016-3562-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
34 Tang F, Tie Y, Tu C, Wei X. Surgical trauma-induced immunosuppression in cancer: Recent advances and the potential therapies. Clin Transl Med 2020;10:199-223. [PMID: 32508035 DOI: 10.1002/ctm2.24] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
35 Dedhia P, Govil A, Mogilishetty G, Alloway RR, Woodle ES, Abu Jawdeh BG. Eculizumab and Belatacept for De Novo Atypical Hemolytic Uremic Syndrome Associated With CFHR3-CFHR1 Deletion in a Kidney Transplant Recipient: A Case Report. Transplant Proc. 2017;49:188-192. [PMID: 28104134 DOI: 10.1016/j.transproceed.2016.11.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
36 Dower J, Dima D, Sieker J, Pilichowska M, Varga C. Eculizumab-induced late erythroid maturation arrest: a case report. Br J Haematol 2020;191:120-2. [PMID: 32671821 DOI: 10.1111/bjh.16936] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Anliker M, Schmidt CQ, Harder MJ, Ganchev G, von Zabern I, Höchsmann B, Schrezenmeier H, Weinstock C. Complement activation by human red blood cell antibodies: hemolytic potential of antibodies and efficacy of complement inhibitors assessed by a sensitive flow cytometric assay. Transfusion 2018;58:2992-3002. [PMID: 30367826 DOI: 10.1111/trf.14893] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
38 Genere L, Bacchetta J, Bertrand Y, Javouhey E, Cheikh N, Sellier-Leclerc AL. Eculizumab and thrombotic microangiopathy after hematopoietic stem cell transplantation: A report on its efficacy and safety in two pediatric patients. Arch Pediatr 2018;25:485-8. [PMID: 30340942 DOI: 10.1016/j.arcped.2018.09.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
39 Zilberman-Itskovich S, Abu-Hamad R, Stark M, Efrati S. Effect of anti-C5 antibody on recuperation from ischemia/reperfusion-induced acute kidney injury. Ren Fail 2019;41:967-75. [PMID: 31662004 DOI: 10.1080/0886022X.2019.1677248] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
40 Teoh CW, Riedl M, Licht C. The alternative pathway of complement and the thrombotic microangiopathies. Transfus Apher Sci. 2016;54:220-231. [PMID: 27160864 DOI: 10.1016/j.transci.2016.04.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
41 Fakhouri F, Fila M, Provôt F, Delmas Y, Barbet C, Châtelet V, Rafat C, Cailliez M, Hogan J, Servais A, Karras A, Makdassi R, Louillet F, Coindre JP, Rondeau E, Loirat C, Frémeaux-Bacchi V. Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation. Clin J Am Soc Nephrol 2017;12:50-9. [PMID: 27799617 DOI: 10.2215/CJN.06440616] [Cited by in Crossref: 94] [Cited by in F6Publishing: 43] [Article Influence: 15.7] [Reference Citation Analysis]
42 Conway EM, Pryzdial ELG. Is the COVID-19 thrombotic catastrophe complement-connected? J Thromb Haemost 2020;18:2812-22. [PMID: 32762081 DOI: 10.1111/jth.15050] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
43 Berentsen S. New Insights in the Pathogenesis and Therapy of Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia. Front Immunol 2020;11:590. [PMID: 32318071 DOI: 10.3389/fimmu.2020.00590] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
44 Frazer-Abel A, Kirschfink M, Prohászka Z. Expanding Horizons in Complement Analysis and Quality Control. Front Immunol 2021;12:697313. [PMID: 34434189 DOI: 10.3389/fimmu.2021.697313] [Reference Citation Analysis]
45 Sartain SE, Turner NA, Moake JL. Brain microvascular endothelial cells exhibit lower activation of the alternative complement pathway than glomerular microvascular endothelial cells. J Biol Chem 2018;293:7195-208. [PMID: 29555686 DOI: 10.1074/jbc.RA118.002639] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 5.8] [Reference Citation Analysis]
46 Hou L, Du Y. Atypical hemolytic uremic syndrome precipitated by thyrotoxicosis: a case report. BMC Pediatr 2020;20:169. [PMID: 32303208 DOI: 10.1186/s12887-020-02082-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Turkmen K, Baloglu I, Ozer H. C3 glomerulopathy and atypical hemolytic uremic syndrome: an updated review of the literature on alternative complement pathway disorders. Int Urol Nephrol 2021. [PMID: 33389509 DOI: 10.1007/s11255-020-02729-y] [Reference Citation Analysis]
48 Regal JF, Burwick RM, Fleming SD. The Complement System and Preeclampsia. Curr Hypertens Rep 2017;19:87. [PMID: 29046976 DOI: 10.1007/s11906-017-0784-4] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 7.6] [Reference Citation Analysis]
49 Mathew RO, Nayer A, Asif A. The endothelium as the common denominator in malignant hypertension and thrombotic microangiopathy. J Am Soc Hypertens 2016;10:352-9. [PMID: 26778772 DOI: 10.1016/j.jash.2015.12.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
50 Thomson N, Ulrickson M. Maintenance eculizumab dose adjustment in the treatment of atypical hemolytic uremic syndrome: a case report and review of the literature. Clin Case Rep 2016;4:773-6. [PMID: 27525082 DOI: 10.1002/ccr3.628] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
51 Formeck C, Swiatecka-Urban A. Extra-renal manifestations of atypical hemolytic uremic syndrome. Pediatr Nephrol 2019;34:1337-48. [PMID: 30109445 DOI: 10.1007/s00467-018-4039-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
52 Bohl SR, Kuchenbauer F, von Harsdorf S, Kloevekorn N, Schönsteiner SS, Rouhi A, Schwarzwälder P, Döhner H, Bunjes D, Bommer M. Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation: A Comparison of Eculizumab Therapy and Conventional Therapy. Biol Blood Marrow Transplant 2017;23:2172-7. [PMID: 28860002 DOI: 10.1016/j.bbmt.2017.08.019] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 6.4] [Reference Citation Analysis]
53 Hanna RM, Barsoum M, Vandross A, Kurtz I, Burwick R. Atypical hemolytic uremic syndrome and complement blockade: established and emerging uses of complement inhibition. Curr Opin Nephrol Hypertens 2019;28:278-87. [PMID: 30865166 DOI: 10.1097/MNH.0000000000000499] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
54 Harder MJ, Kuhn N, Schrezenmeier H, Höchsmann B, von Zabern I, Weinstock C, Simmet T, Ricklin D, Lambris JD, Skerra A, Anliker M, Schmidt CQ. Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation. Blood 2017;129:970-80. [PMID: 28028023 DOI: 10.1182/blood-2016-08-732800] [Cited by in Crossref: 70] [Cited by in F6Publishing: 64] [Article Influence: 11.7] [Reference Citation Analysis]
55 Wijnsma KL, Duineveld C, Wetzels JFM, van de Kar NCAJ. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use. Pediatr Nephrol 2019;34:2261-77. [PMID: 30402748 DOI: 10.1007/s00467-018-4091-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
56 Riedemann NC, Habel M, Ziereisen J, Hermann M, Schneider C, Wehling C, Kirschfink M, Kentouche K, Guo R. Controlling the anaphylatoxin C5a in diseases requires a specifically targeted inhibition. Clin Immunol 2017;180:25-32. [PMID: 28366510 DOI: 10.1016/j.clim.2017.03.012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
57 Kazzaz NM, McCune WJ, Knight JS. Treatment of catastrophic antiphospholipid syndrome. Curr Opin Rheumatol 2016;28:218-27. [PMID: 26927441 DOI: 10.1097/BOR.0000000000000269] [Cited by in Crossref: 42] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
58 Bauer AT, Gorzelanny C, Gebhardt C, Pantel K, Schneider SW. Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities. Cancer Treatment Reviews 2022;102:102322. [DOI: 10.1016/j.ctrv.2021.102322] [Reference Citation Analysis]
59 Raina R, Krishnappa V, Blaha T, Kann T, Hein W, Burke L, Bagga A. Atypical Hemolytic-Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment. Ther Apher Dial 2019;23:4-21. [PMID: 30294946 DOI: 10.1111/1744-9987.12763] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
60 Burwick RM, Burwick N, Feinberg BB. Response: Maternal and cord C5a in response to eculizumab. Blood 2015;126:279-80. [PMID: 26160189 DOI: 10.1182/blood-2015-06-642553] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
61 Chung C. New Therapeutic Targets and Treatment Options for Thrombotic Microangiopathy: Caplacizumab and Ravulizumab. Ann Pharmacother 2021;55:330-43. [PMID: 32715723 DOI: 10.1177/1060028020941852] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
62 Brusov OS, Karpova NS, Oleichik IV, Faktor MI, Sizov SV. [The decrease in procoagulant activity of blood during combined therapy with antidepressants and antipsychotics in patients with endogenous mental disorders]. Zh Nevrol Psikhiatr Im S S Korsakova 2021;121:55-60. [PMID: 34932286 DOI: 10.17116/jnevro202112111155] [Reference Citation Analysis]
63 De Luca C, Colangelo AM, Alberghina L, Papa M. Neuro-Immune Hemostasis: Homeostasis and Diseases in the Central Nervous System. Front Cell Neurosci 2018;12:459. [PMID: 30534057 DOI: 10.3389/fncel.2018.00459] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 10.8] [Reference Citation Analysis]
64 Tuchscherer A, Chemnitz J. [Hemolytic anemia]. Internist (Berl) 2015;56:1000-8. [PMID: 26245867 DOI: 10.1007/s00108-015-3661-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
65 Singh AK, Malviya R. Coagulation and inflammation in cancer: Limitations and prospects for treatment. Biochim Biophys Acta Rev Cancer 2022;:188727. [PMID: 35378243 DOI: 10.1016/j.bbcan.2022.188727] [Reference Citation Analysis]
66 Vilardouro AS, Cachão J, Rodrigues M, Durão F, Costa-Reis P, Sandes AR, Silva JED, Boto L, Stone R. Hemolytic-uremic syndrome: 24 years' experience of a pediatric nephrology unit. J Bras Nefrol 2022:S0101-28002022005021402. [PMID: 35385571 DOI: 10.1590/2175-8239-JBN-2021-0206] [Reference Citation Analysis]
67 Barnum SR, Bubeck D, Schein TN. Soluble Membrane Attack Complex: Biochemistry and Immunobiology. Front Immunol 2020;11:585108. [PMID: 33240274 DOI: 10.3389/fimmu.2020.585108] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
68 Reis ES, Berger N, Wang X, Koutsogiannaki S, Doot RK, Gumas JT, Foukas PG, Resuello RRG, Tuplano JV, Kukis D, Tarantal AF, Young AJ, Kajikawa T, Soulika AM, Mastellos DC, Yancopoulou D, Biglarnia AR, Huber-Lang M, Hajishengallis G, Nilsson B, Lambris JD. Safety profile after prolonged C3 inhibition. Clin Immunol 2018;197:96-106. [PMID: 30217791 DOI: 10.1016/j.clim.2018.09.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
69 Cody EM, Dixon BP. Hemolytic Uremic Syndrome. Pediatric Clinics of North America 2019;66:235-46. [DOI: 10.1016/j.pcl.2018.09.011] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
70 Winnicki W, Pichler P, Mechtler K, Imre R, Steinmacher I, Sengölge G, Knafl D, Beilhack G, Wagner L. A novel approach to immunoapheresis of C3a/C3 and proteomic identification of associates. PeerJ 2019;7:e8218. [PMID: 31871840 DOI: 10.7717/peerj.8218] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
71 Jokiranta TS. HUS and atypical HUS. Blood. 2017;129:2847-2856. [PMID: 28416508 DOI: 10.1182/blood-2016-11-709865] [Cited by in Crossref: 124] [Cited by in F6Publishing: 101] [Article Influence: 24.8] [Reference Citation Analysis]
72 Chiang KC, Imig JD, Kalantar-Zadeh K, Gupta A. Kidney in the net of acute and long-haul coronavirus disease 2019: a potential role for lipid mediators in causing renal injury and fibrosis. Curr Opin Nephrol Hypertens 2022;31:36-46. [PMID: 34846312 DOI: 10.1097/MNH.0000000000000750] [Reference Citation Analysis]
73 Raina R, Grewal MK, Radhakrishnan Y, Tatineni V, DeCoy M, Burke LL, Bagga A. Optimal management of atypical hemolytic uremic disease: challenges and solutions. Int J Nephrol Renovasc Dis 2019;12:183-204. [PMID: 31564951 DOI: 10.2147/IJNRD.S215370] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
74 Bazzan M, Todros T, Tedeschi S, Ardissino G, Cardaropoli S, Stella S, Montaruli B, Marchese C, Roccatello D, Cugno M. Genetic and molecular evidence for complement dysregulation in patients with HELLP syndrome. Thromb Res 2020;196:167-74. [PMID: 32890900 DOI: 10.1016/j.thromres.2020.08.038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Ricklin D, Reis ES, Lambris JD. Complement in disease: a defence system turning offensive. Nat Rev Nephrol. 2016;12:383-401. [PMID: 27211870 DOI: 10.1038/nrneph.2016.70] [Cited by in Crossref: 248] [Cited by in F6Publishing: 246] [Article Influence: 41.3] [Reference Citation Analysis]
76 Gorman DM, Lee J, Payne CD, Woodruff TM, Clark RJ. Chemical synthesis and characterisation of the complement C5 inhibitory peptide zilucoplan. Amino Acids 2021;53:143-7. [PMID: 33398524 DOI: 10.1007/s00726-020-02921-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
77 Zhang K, Lu Y, Harley KT, Tran MH. Atypical Hemolytic Uremic Syndrome: A Brief Review. Hematol Rep 2017;9:7053. [PMID: 28626544 DOI: 10.4081/hr.2017.7053] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
78 Fakhouri F, Loirat C. Anticomplement Treatment in Atypical and Typical Hemolytic Uremic Syndrome. Seminars in Hematology 2018;55:150-8. [DOI: 10.1053/j.seminhematol.2018.04.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
79 Talaat IM, Elemam NM, Saber-ayad M. Complement System: An Immunotherapy Target in Colorectal Cancer. Front Immunol 2022;13:810993. [DOI: 10.3389/fimmu.2022.810993] [Reference Citation Analysis]
80 Luo S, Hu D, Wang M, Zipfel PF, Hu Y. Complement in Hemolysis- and Thrombosis- Related Diseases. Front Immunol 2020;11:1212. [PMID: 32754149 DOI: 10.3389/fimmu.2020.01212] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
81 Stefanovic V. The Extended Use of Eculizumab in Pregnancy and Complement Activation⁻Associated Diseases Affecting Maternal, Fetal and Neonatal Kidneys-The Future Is Now? J Clin Med 2019;8:E407. [PMID: 30909646 DOI: 10.3390/jcm8030407] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
82 Muff-Luett M, Sanderson KR, Engen RM, Zahr RS, Wenderfer SE, Tran CL, Sharma S, Cai Y, Ingraham S, Winnicki E, Weaver DJ, Hunley TE, Kiessling SG, Seamon M, Woroniecki R, Miyashita Y, Xiao N, Omoloja AA, Kizilbash SJ, Mansuri A, Kallash M, Yu Y, Sherman AK, Srivastava T, Nester CM. Eculizumab exposure in children and young adults: indications, practice patterns, and outcomes-a Pediatric Nephrology Research Consortium study. Pediatr Nephrol 2021;36:2349-60. [PMID: 33693990 DOI: 10.1007/s00467-021-04965-5] [Reference Citation Analysis]
83 Vujkovic-Cvijin I, Sortino O, Verheij E, Wit FW, Kootstra NA, Sellers B, Schim van der Loeff M, Belkaid Y, Reiss P, Sereti I. The complement pathway is activated in people with HIV and is associated with non-AIDS comorbidities. J Infect Dis 2021:jiab096. [PMID: 33606018 DOI: 10.1093/infdis/jiab096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Hossain MA, Ahmed N, Gupta V, Bajwa R, Alidoost M, Asif A, Vachharajani T. Post-traumatic thrombotic microangiopathy: What trauma surgeons need to know? Chin J Traumatol 2021;24:69-74. [PMID: 33518399 DOI: 10.1016/j.cjtee.2021.01.004] [Reference Citation Analysis]
85 Rodríguez-rivera C, Garcia MM, Molina-álvarez M, González-martín C, Goicoechea C. Clusterin: Always protecting. Synthesis, function and potential issues. Biomedicine & Pharmacotherapy 2021;134:111174. [DOI: 10.1016/j.biopha.2020.111174] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
86 Santiesteban-Lores LE, Amamura TA, da Silva TF, Midon LM, Carneiro MC, Isaac L, Bavia L. A double edged-sword - The Complement System during SARS-CoV-2 infection. Life Sci 2021;272:119245. [PMID: 33609539 DOI: 10.1016/j.lfs.2021.119245] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
87 Zuckerman R, Asif A, Costanzo EJ, Vachharajani T. Complement activation in atypical hemolytic uremic syndrome and scleroderma renal crisis: a critical analysis of pathophysiology. J Bras Nefrol 2018;40:77-81. [PMID: 29796581 DOI: 10.1590/2175-8239-JBN-3807] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
88 Ozen A, Comrie WA, Ardy RC, Domínguez Conde C, Dalgic B, Beser ÖF, Morawski AR, Karakoc-Aydiner E, Tutar E, Baris S, Ozcay F, Serwas NK, Zhang Y, Matthews HF, Pittaluga S, Folio LR, Unlusoy Aksu A, McElwee JJ, Krolo A, Kiykim A, Baris Z, Gulsan M, Ogulur I, Snapper SB, Houwen RHJ, Leavis HL, Ertem D, Kain R, Sari S, Erkan T, Su HC, Boztug K, Lenardo MJ. CD55 Deficiency, Early-Onset Protein-Losing Enteropathy, and Thrombosis. N Engl J Med 2017;377:52-61. [PMID: 28657829 DOI: 10.1056/NEJMoa1615887] [Cited by in Crossref: 74] [Cited by in F6Publishing: 35] [Article Influence: 14.8] [Reference Citation Analysis]
89 Yıldız S, Demirkan F. What is the evidence for the role of therapeutic apheresis in the management of complement-associated thrombotic microangiopathies? Transfus Apher Sci 2018;57:31-4. [PMID: 29506907 DOI: 10.1016/j.transci.2018.02.013] [Reference Citation Analysis]
90 Zununi Vahed S, Rahbar Saadat Y, Ardalan M. Thrombotic microangiopathy during pregnancy. Microvasc Res 2021;138:104226. [PMID: 34252400 DOI: 10.1016/j.mvr.2021.104226] [Reference Citation Analysis]
91 Yoshida Y, Kato H, Nangaku M. Atypical hemolytic uremic syndrome. Ren Replace Ther 2017;3. [DOI: 10.1186/s41100-016-0088-1] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
92 Cheong HI, Jo SK, Yoon SS, Cho H, Kim JS, Kim YO, Koo JR, Park Y, Park YS, Shin JI, Yoo KH, Oh D. Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea. J Korean Med Sci 2016;31:1516-28. [PMID: 27550478 DOI: 10.3346/jkms.2016.31.10.1516] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
93 Azoulay E, Knoebl P, Garnacho-Montero J, Rusinova K, Galstian G, Eggimann P, Abroug F, Benoit D, von Bergwelt-Baildon M, Wendon J, Scully M. Expert Statements on the Standard of Care in Critically Ill Adult Patients With Atypical Hemolytic Uremic Syndrome. Chest 2017;152:424-34. [PMID: 28442312 DOI: 10.1016/j.chest.2017.03.055] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
94 Brusov OS, Oleichik IV, Karpova NS, Faktor MI, Sizov SV. [Correlations between thrombodynamic parameters of coagulation and negative syndromes in patients with schizophrenia]. Zh Nevrol Psikhiatr Im S S Korsakova 2020;120:86-91. [PMID: 33459546 DOI: 10.17116/jnevro202012012186] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Palma LM, Langman CB. Critical appraisal of eculizumab for atypical hemolytic uremic syndrome. J Blood Med 2016;7:39-72. [PMID: 27110144 DOI: 10.2147/JBM.S36249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.3] [Reference Citation Analysis]
96 Gavriilaki E, Anagnostopoulos A, Mastellos DC. Complement in Thrombotic Microangiopathies: Unraveling Ariadne's Thread Into the Labyrinth of Complement Therapeutics. Front Immunol 2019;10:337. [PMID: 30891033 DOI: 10.3389/fimmu.2019.00337] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 11.7] [Reference Citation Analysis]
97 Berger BE. The Alternative Pathway of Complement and the Evolving Clinical-Pathophysiological Spectrum of Atypical Hemolytic Uremic Syndrome. Am J Med Sci 2016;352:177-90. [PMID: 27524217 DOI: 10.1016/j.amjms.2016.05.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
98 Hunter AC, Moghimi SM. Smart polymers in drug delivery: a biological perspective. Polym Chem 2017;8:41-51. [DOI: 10.1039/c6py00676k] [Cited by in Crossref: 41] [Article Influence: 8.2] [Reference Citation Analysis]
99 Kato H, Miyakawa Y, Hidaka Y, Inoue N, Ito S, Kagami S, Kaname S, Matsumoto M, Mizuno M, Matsuda T, Shimono A, Maruyama S, Fujimura Y, Nangaku M, Okada H. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance. Clin Exp Nephrol 2019;23:65-75. [PMID: 29959568 DOI: 10.1007/s10157-018-1609-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
100 Wehling C, Amon O, Bommer M, Hoppe B, Kentouche K, Schalk G, Weimer R, Wiesener M, Hohenstein B, Tönshoff B, Büscher R, Fehrenbach H, Gök ÖN, Kirschfink M. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders. Clin Exp Immunol 2017;187:304-15. [PMID: 27784126 DOI: 10.1111/cei.12890] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 7.2] [Reference Citation Analysis]
101 McDonald CR, Tran V, Kain KC. Complement Activation in Placental Malaria. Front Microbiol 2015;6:1460. [PMID: 26733992 DOI: 10.3389/fmicb.2015.01460] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
102 Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet 2017;390:681-96. [PMID: 28242109 DOI: 10.1016/S0140-6736(17)30062-4] [Cited by in Crossref: 202] [Cited by in F6Publishing: 108] [Article Influence: 40.4] [Reference Citation Analysis]
103 Lokki AI, Haapio M, Heikkinen-Eloranta J. Eculizumab Treatment for Postpartum HELLP Syndrome and aHUS-Case Report. Front Immunol 2020;11:548. [PMID: 32308654 DOI: 10.3389/fimmu.2020.00548] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
104 Ariceta G, Dixon BP, Kim SH, Kapur G, Mauch T, Ortiz S, Vallee M, Denker AE, Kang HG, Greenbaum LA; 312 Study Group. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int 2021;100:225-37. [PMID: 33307104 DOI: 10.1016/j.kint.2020.10.046] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
105 Roumenina LT, Rayes J, Frimat M, Fremeaux-Bacchi V. Endothelial cells: source, barrier, and target of defensive mediators. Immunol Rev 2016;274:307-29. [PMID: 27782324 DOI: 10.1111/imr.12479] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 10.8] [Reference Citation Analysis]
106 Morser J, Shao Z, Nishimura T, Zhou Q, Zhao L, Higgins J, Leung LLK. Carboxypeptidase B2 and N play different roles in regulation of activated complements C3a and C5a in mice. J Thromb Haemost 2018;16:991-1002. [PMID: 29383821 DOI: 10.1111/jth.13964] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
107 Galbusera M, Noris M, Gastoldi S, Bresin E, Mele C, Breno M, Cuccarolo P, Alberti M, Valoti E, Piras R, Donadelli R, Vivarelli M, Murer L, Pecoraro C, Ferrari E, Perna A, Benigni A, Portalupi V, Remuzzi G. An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome. Am J Kidney Dis 2019;74:56-72. [PMID: 30851964 DOI: 10.1053/j.ajkd.2018.11.012] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 8.7] [Reference Citation Analysis]
108 van den Brand JA, Verhave JC, Adang EM, Wetzels JF. Cost-effectiveness of eculizumab treatment after kidney transplantation in patients with atypical haemolytic uraemic syndrome. Nephrology Dialysis Transplantation 2017;32:i115-22. [DOI: 10.1093/ndt/gfw353] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]